BioSpace News Archive

AmerisourceBergen Corporation (NYSE: ABC) today announced that it plans to release its results for the Third Quarter Fiscal 2020 on Wednesday, August 5, 2020, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2020. Participating in the conference call will be: Steven H. Collis, Chairman, President & Ch

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic:.

TerrAscend Corp. (CSE:TER) (OTCQX: TRSSF) (“TerrAscend” or the “Company”) today announced that its 2020 annual general meeting of shareholders (the “AGM”) will be held on August 18, 2020 . As a result of the ongoing impact of the COVID-19 pandemic and in accordance with continued public health measures, t

Castle Biosciences, Inc. (Nasdaq: CSTL), announced today that the underwriters of its recently closed underwritten public offering of 2,000,000 shares of its common stock have exercised in full their option to purchase an additional 300,000 shares of common stock at the public offering price of $37.00 per share, less underwriting discounts and commissions. The gross proceeds to Castle Biosciences from the offering, inc

AVRICORE HEALTH INC. is pleased to announce that it has entered into shares for debt agreements, to satisfy an aggregate of $126,949 of the Company’s outstanding debts.

Aurora Spine Corporation announced the promotion of Chad Clouse to the position of Chief Financial Officer, effective July 2, 2020.

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services, announced that it plans to release its second quarter 2020 financial results on Tuesday, July 28, 2020.

FDA’s “Enforcement Policy” and Orexo’s strong financial position enable investments in an accelerated commercialization of its scientifically proven digital therapies

XCART technology platform is a significantly differentiated, proprietary approach to personalized CAR T therapy for the treatment of multiple tumor types of B-cell Non-Hodgkin lymphoma (NHL)

Halberd Corporation announced the establishment of a subsidiary in the United Kingdom to facilitate access to European research facilities and markets.